2013, Number 3
<< Back Next >>
Rev Ciencias Médicas 2013; 17 (3)
Characterization of Type-III Ehlers–Danlos Syndrome
Campo DMC, Fortún CA, Beades MA, Gato SY, Valdés SC
Language: Spanish
References: 18
Page: 16-24
PDF size: 122.30 Kb.
ABSTRACT
Introduction: Ehlers–Danlos Syndrome (EDS) is a heterogeneous group of
inherited connective tissue disorders, caused by mutations in the genes that codify
fibrillar collagen or the enzymes implicated in modifying post-translational collagen
that affects skin, joints and blood vessels. Frequently, the clinical picture presents
articular hypermobility with hyperextension associated with cutaneous anomalies.
Objective: to characterize Type-III Ehlers–Danlos Syndrome in Pinar del Rio
province.
Material and method: an applied, observational, descriptive and cross-sectional
study that included 305 children (from 5 to 18 years old) suffering from type-III
Ehlers–Danlos Syndrome (EDS) to the diagnosis of typical articular manifestations
of the disease, along with an assessment that involved cardiology, ophthalmology,
physical-therapy specialties; performing at the same time a coagulation assay and
peripheral blood smear.
Results: no sex prevalence was found and family history was present in more than
the half of patients, where maternal line prevailed. Hemorrhagic familial trend was
positive in 36 cases. The main manifestations found in these patients were
described to this health condition, the existence of mucous-cutaneous bleeding
predominated or as a consequence of invasive procedures in 181 children; which
was associated with the presence of disorders associated with macro-platelets and
the finding of disperse platelets in peripheral-blood smears.
Conclusions: the results evidenced the presence of qualitative platelet disorders
that must be evaluated by means of much more specific coagulation assays, not in
existence in the province, which must include aggregation and platelet function.
REFERENCES
WW Tan P, Song C, Lalonde D. Ehlers-Danlos syndrome associated with cleft lip and palate. Can J Plast Surg. 2009[cited dec.2012]; 17(4): e24-e26. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827283/
Bravo Jaime F. Síndrome de Ehlers-Danlos con especial énfasis en el síndrome de hiperlaxitud articular. Rev. méd. Chile [revista en la Internet]. 2009 Nov [citado 2013 Abr 09]; 137(11): 1488-1497. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034- 98872009001100013&lng=es
Bravo J. Significado e importancia de estudiar a las personas con hiperlaxitud articular. Rev Chil reumatol 2008;24:4-5.
Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos Syndromes: Revised Nosology, Villefranche, 1997. Am J Med Genet[internet]. 1998 Apr 28[cited nov. 2012]; 77(1):31-7. Available from: http://prettyill.com/downloads/Ehlers-Danlos_Syndrome_Revised_Nosology.pdf
Child AH. Joint Hypermobility Syndrome: inherited disorder of collagen synthesis. J Rheumatol 1986; 13(2): 239-42.
Hermanns-Le T, Pierard GE. Ultra structural alterations of elastic fibers and other dermal components in Ehlers-Danlos syndrome of the hypermobile type. Ann J Dermatopathol[internet] 2007[cited nov. 2012]; 29(4):370-3. Available from: http://journals.lww.com/pages/login.aspx?ContextUrl=%2famjdermatopathology% 2fsecure%2fpages%2fpurchase.aspx%3fan%3d00000372-200708000-00007
Zweers MC, Hakim AJ, Grahame R, Schalkwiik J. Joint hypermobility syndromes: the pathophysiologic role of Tenascin-X gene defects [review]. Arthritis Rheum[internet] 2004[cited nov. 2012]; 50(9): 2742-9. Available from: http://onlinelibrary.wiley.com/doi/10.1002/art.20488/pdf
Levy H. Síndrome de Ehlers Danlos tipo hiperlaxitud. Revisión (Sed tipo III, Síndorme de Ehlers Danlos tipo III. Asociación Síndromes de Ehlers Danlos e Hiperlaxitud 2001-2010 (actualizado 2011 Ene 25; citado 2011 Feb 20). Disponible en: https://sites.google.com/site/rededargentina/sindrome-de-ehlers-danlos-tipohiperlaxitud
Yenicesu I, Ucan D, Soysal A, Büyükasik Y, Gümrük F. Platelet reliase defect in a child with Ehlers-Danlos syndrome. Pediatr Hematol Oncol[internet] 2000[cited nov. 2012];17(2):193-4. Available from: http://informahealthcare.com/doi/pdf/10.1080/088800100276587
Prockop D J, Czarny-Ralajczak M. Disorders of connective tissue. In: Harrison's Principles of Internal Medicine. 17th edition. Tomo II. New York: Mc Graw Hill; 2008: 2461-8.
Watanabe A, Kosho T, Wada T, Sakai N, Fujimoto M, Fukushima Y, Shimada T. Genetic Aspects of the Vascular Type of Ehlers-Danlos Syndrome. Circ J[internet] 2007[cited nov. 2012];71(2): 261-265. Available from: https://www.jstage.jst.go.jp/article/circj/71/2/71_2_261/article
Miranda-Gómez A. Hiperelasticidad cutánea e hiperlaxitud articular. Rev Mex Dermatología[internet] 2008[citado nov. 2012];52(3): 248-55. Disponible en: http://www.nietoeditores.com.mx/download/Dermatologia/mayojunio2008/ Derma2008-52%283%29111-20.pdf
Tofts LJ, Elliott EJ, Munns C, Pacey V, Sillence DO. The differential diagnosis of children with joint hypermobility: review of the literature. Pediatric Rheumatology[internet] 2009[cited nov. 2012];7:1-10. Available from: http://www.ped-rheum.com/content/7/1/1
Keer H, Elsevier G. Hipermobility, fibromyalgia and chronic pain. Reumatology 2010;26:194-202.
EUA. Asociación Síndromes de Ehlers Danlos e Hiperlaxitud. Tratamiento del Síndrome de Ehlers Danlos. [Internet]. 2010 Mar 14. Disponible en: http://asedh.org/quesh.php [citado 2011 Ene 24]
McDonnell NB, Gorman BL, Mandel KW, Schurman SH, Assanah-Carroll A, Mayer SA, Najjar SS, Francomano CA. Echocardiographicfindings in classical and hypermobile Ehlers-Danlos syndromes. Am J Med Genet[internet] 2006[citado nov. 2012];140(2):129-36. Available from: http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.31035/pdf
Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. Journal of Cell Science[internet] 2004[cited nov. 2012];117:3415-25 . Available from: http://jcs.biologists.org/content/117/16/3415.long
Onel D, Ulutin S B, Ulutin O N. Platelet defect in a case of Ehlers-Danlos syndrome. Acta Haematol 1973;50:238-44.